# Towards Cure Via Only Ultra-short ICB in CSCC

> **NCT06823479** · PHASE2 · RECRUITING · sponsor: **The Netherlands Cancer Institute** · enrollment: 41 (estimated)

## Conditions studied

- Cutaneous Squamous Cell Carcinoma (CSCC)
- Cutaneous Squamous Cell Cancer
- Cutaneous Squamous Cell Carcinoma of the Head and Neck
- Cutaneous Squamous Cell Carcinoma

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Ipilumimab

## Key facts

- **NCT ID:** NCT06823479
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-14
- **Primary completion:** 2029-02
- **Final completion:** 2029-02
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2025-05-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06823479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06823479, "Towards Cure Via Only Ultra-short ICB in CSCC". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06823479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*